27-Feb-2026
No headlines found.
Maximus Reports Fiscal Year 2026 First Quarter Results
Business Wire (Thu, 5-Feb 6:30 AM ET)
Business Wire (Tue, 27-Jan 7:30 AM ET)
Maximus Schedules Fiscal 2026 First Quarter Conference Call
Business Wire (Thu, 8-Jan 9:00 AM ET)
Maximus Announces Quarterly Cash Dividend Increase of 10% to $0.33 per Share
Business Wire (Tue, 6-Jan 4:30 PM ET)
Maximus Inc designs, develops, and delivers programs enabling people to access vital government services. It translates health and human services public policy into operating models that achieve outcomes for governments at scale. The company covers a broad array of services, including the operation of large health insurance eligibility and enrollment programs; clinical services, including assessments, appeals, and independent medical reviews; and technology services. The company operates through the following segments: U.S. Federal Services, U.S. Services, and Outside the U.S. A majority of its revenue is derived from the U.S. Federal Services segment, which engages with various U.S. federal government agencies to deliver clinical services, maintenance services, and technology solutions.
Maximus trades on the NYSE stock market under the symbol MMS.
As of February 27, 2026, MMS stock price declined to $75.61 with 793,048 million shares trading.
MMS has a beta of 0.26, meaning it tends to be less sensitive to market movements. MMS has a correlation of 0.01 to the broad based SPY ETF.
MMS has a market cap of $4.12 billion. This is considered a Mid Cap stock.
Last quarter Maximus reported $1 billion in Revenue and $1.85 earnings per share. This fell short of revenue expectation by $-44 million and exceeded earnings estimates by $.02.
In the last 3 years, MMS traded as high as $100.00 and as low as $63.77.
The top ETF exchange traded funds that MMS belongs to (by Net Assets): VTI, IJH, VB, IWM, VBR.
MMS has underperformed the market in the last year with a return of +15.5%, while the SPY ETF gained +18.5%. In the last 3 month period, MMS fell short of the market, returning -11.9%, while SPY returned +1.2%. However, in the most recent 2 weeks MMS has outperformed the stock market by returning +1.2%, while SPY returned +0.6%.
MMS support price is $73.63 and resistance is $77.67 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that MMS shares will trade within this expected range on the day.